Research Article

Development, Characterization, and Evaluation of SLN-Loaded Thermoresponsive Hydrogel System of Topotecan as Biological Macromolecule for Colorectal Delivery

R. Xing, 1,2 O. Mustapha, 3 T. Ali, 3 M. Rehman, 4 S. S. Zaidi, 3 A. Baseer, 5 S. Batool, 6 M. Mukhtiar, 7 S. Shafique, 3 M. Malik, 6 S. Sohail, 6 Z. Ali, 6 F. Zahid, 6 A. Zeb, 8 F. Shah, 8 A. Yousef, 9 and F. Din 10

1Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
2Beijing Key Laboratory of Bio-characteristic Profiling for Evaluation of Rational Drug Use, Beijing 100038, China
3Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, DOW University of Health Sciences, 74200 Karachi, Pakistan
4HEJ. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan
5Department of Pharmacy, Abasyn University Peshawar, KPK, Pakistan
6Nanomedicine Research Group, Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
7Department of Pharmacy, Faculty of Medical and Health Sciences, University of Poonch Rawalakot, AJK, Pakistan
8Riphah Institute of Pharmaceutical Sciences, Riphah International University, Sector G-7/4, Islamabad 44000, Pakistan
9Department of Pharmacy, COMSATS University Islamabad, Lahore Campus, Lahore 54000, Pakistan

Correspondence should be addressed to F. Din; fudin@qau.edu.pk

Received 19 March 2021; Accepted 21 June 2021; Published 5 July 2021

Academic Editor: Luisa Di Stefano

Copyright © 2021 R. Xing et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Chemotherapeutic drugs cause severe toxicities if administered unprotected, without proper targeting, and controlled release. In this study, we developed topotecan- (TPT-) loaded solid lipid nanoparticles (SLNs) for their chemotherapeutic effect against colorectal cancer. The TPT-SLNs were further incorporated into a thermoresponsive hydrogel system (TRHS) (TPT-SLNs-TRHS) to ensure control release and reduce toxicity of the drug. Microemulsion technique and cold method were, respectively, used to develop TPT-SLNs and TPT-SLNs-TRHS. Particle size, polydispersive index (PDI), and incorporation efficiency (IE) of the TPT-SLNs were determined. Similarly, gelation time, gel strength, and bioadhesive force studies of the TPT-SLNs-TRHS were performed. Additionally, in vitro release and pharmacokinetic and antitumour evaluations of the formulation were done. Results. TPT-SLNs have uniformly distributed particles with mean size in nanorange (174 nm) and IE of ~90%. TPT-SLNs-TRHS demonstrated suitable gelation properties upon administration into the rat’s rectum. Moreover, drug release was exhibited in a control manner over an extended period of time for the incorporated TPT. Pharmacokinetic studies showed enhanced bioavailability of the TPT with improved plasma concentration and AUC. Further, it showed significantly enhanced antitumour effect in tumour-bearing mice as compared to the test formulations. Conclusion. It can be concluded that SLNs incorporated in TRHS could be a potential source of the antitumour drug delivery with better control of the drug release and no toxicity.

1. Introduction

Topotecan (TPT) is a water soluble compound, a synthetic derivative of camptothecin [1]. TPT possesses significant antineoplastic activity in colorectal and small cell lung cancer. It disrupts enzyme topoisomerase 1 and inhibits replication of a rapidly dividing cell. A major problem of camptothecin class drugs is their hydrolysis of lactone ring
to the inactive carboxylate group at physiologic pH, decreasing the efficacy of the drug [2]. These compounds exhibit reversible pH-dependent hydrolysis at alkaline and neutral pH. There is a need to formulate a dosage form of drug maintaining its active form and an efficient sustained release. Various nanoparticle-mediated drug delivery systems are currently being investigated to check the chemical stability and improve the release profile of the antitumour drugs like TPT [1, 3]. These drug delivery systems include lipid-based nanoparticles [4], mesoporous silica nanoparticles [5], solid lipid nanoparticles (SLNs) [6], and liposomes [7]. However, most of these studies did not report the complete profile of TPT including its antitumour capability, therapeutic efficacy, and safety profile, most particularly after rectal administration. It is for this reason that we develop a new concept of drug-loaded solid lipid nanoparticle in gel for rectal delivery, which may not only enhance the therapeutic efficacy but also reduce the toxicity of the chemotherapeutic agents.

SLNs are currently focused as an alternate drug delivery system for improved access of chemotherapeutic drug to the target site [8–10]. Similarly, SLNs are reported to protect incorporated drug and offer controlled release of the drug in vivo [11–13]. An SLN-based nanocarrier system has the capability to abridge some of the drawbacks of traditional anticancer therapies, including lack of selectivity, induced tissue toxicity, reduced uptake by tumour cells, and instability [14–16]. Although being very effective for drug delivery, the SLNs sometimes demonstrate the burst release of its incorporated drugs leading to severe toxicity and failure of the therapy [17, 18]. To cope with this problem and ensure the controlled release of the incorporated drug, we incorporated the SLNs in a temperature-sensitive hydrogel to protect its immediate release. Temperature-sensitive hydrogels are prepared using poloxamer solutions (P407/P188/H2O) [19, 20]. These hydrogels were liquids at room temperature and gelled at body temperature [21, 22], preferred for use in injectable [23] ocular [24] and rectal [25] administration as controlled drug delivery systems. Moreover, they exhibited improved blood stream concentration of the drug in rats and humans [26].

In this study, we developed topotecan-loaded solid lipid nanoparticles (TPT-SLNs) and incorporated them in the thermoresponsive hydrogel system (TRHS) to obtain TPT-loaded SLN-mediated TRHS (TPT-SLNs-TRHS). The TPT-SLNs were a dispersion of TPT prepared by the microemulsion method, where the TRHS was a transparent hydrogel system. The SLNs and TRHS in this system (TPT-SLNs-TRHS) maintained controlled release of the TPT and prevented toxicity to the local tissues. Moreover, the TPT-SLNs-TRHS was convenient for rectal administration as it remained free flowing at below 30°C and converted to gel form at physiological conditions. It showed no signs of leakage and was well adhered to the mucosal lining of the rectum. The physicochemical and rheological behaviours, TEM, dissolution, and pharmacokinetic studies of the TPT-SLNs-TRHS were performed. Similarly, morphology and antitumour efficacy of the TPT-SLNs-TRHS were executed in xenograft nude mice.

2. Materials and Methods

2.1. Materials. Topotecan (TPT), tricaprin, and triethanolamine were purchased from Tokyo Chem. Inc. (Tokyo, Japan). Poloxamer 407 and poloxamer 188 were bought from Merk (Karachi, Pakistan). Tween 80 (polysorbate 80) was gifted by Vision Pharma Islamabad Pakistan. Span 20 was kindly gifted by Hanyang University, South Korea. The semi-permeable membrane tubes were purchased from Medicell Membranes Limited (London, UK). All the other chemical reagents used in the study were utilised without any further purification.

2.2. Animals. Male Sprague-Dawley rats and female arrhythmic nude mice were purchased from Ripah International University, Islamabad, Pakistan. They were caged separately at 23 ± 2°C and a relative humidity of 55 ± 2% before the experiments. Water and food access was provided to the animals. Food access was stopped 12 h before the experiments. Ethical considerations for animal studies were followed during the study, especially those provided by the NIH and approved by bioethical committee Quaid-i-Azam University, Islamabad.

2.3. Fabrication of TPT-Loaded SLNs. TPT-SLNs were prepared by microemulsion technique with a little modification [27, 28]. A mixture of Span 20 and tricaprin was added to Tween 80 at elevated temperature, followed by addition of 1 mL distilled water under continuous stirring, until a transparent microemulsion was formed. Further, TPT was slowly mixed into the microemulsion with constant stirring. Additionally, 1 part of this hot microemulsion was then disseminated into 9 parts of cold water (2-4°C) under vigorous stirring (13,400 rpm) for 10 min, IKA Ultra-Turrax, Guangzhou, China) resulting in the preparation of SLN dispersion [1, 29]. These SLN dispersions contained 1 g of TPT and 0.5% (w/v) lipid content and stabilized by 0.5% (w/v) of surfactant and cosurfactant (Tween 80: Span 20, 4:1 ratio).

2.4. Characterization of TPT-Loaded SLNs

2.4.1. Analysis of Particle Size. TPT-SLNs were analysed for mean particle size and zeta analysis by dynamic light scattering using Zetasizer Nano ZS 90 (Malvern Instruments, Worcestershire, UK), equipped with a Helium-Neon laser that operated at a wavelength of 635 nm at 90° angle. Temperature of the systems was maintained at 25°C for analysis. A sample of 10 μg TPT-SLN was dispersed in 1 mL of deionized water. It was then vortexed for 1 minute followed by the particle size analysis. Software (version 6.34, Malvern Instruments, Worcestershire, UK) was used to determine the mean particle size and distribution. The results were displayed in triplicate [30, 31].

2.5. Incorporation Efficiency and Total Drug Content. To determine incorporation efficiency (IE) of TPT-SLNs, 1 mL of the sample was analysed by centrifugation method. Momentarily, 1 mL of the TPT-SLN dispersion was mixed with four parts of normal saline followed by centrifugation at 24,000 rpm for 120 min at 5°C using a centrifuge machine.
Fabrication of the TPT-SLNs-TRHS. TPT-SLNs-TRHS was developed by dissolving 1 g of TPT-SLN per 10 mL of poloxamer solution at 2-5°C with constant stirring. Poloxamer solution contained P 407, P 188, and distilled water at the ratio of 90:10 (v/v). The eluent was monitored at 381 nm with a flow rate of 0.7 mL/min and injection volume of 10 μL [1, 32]. This method was modified for accurate results. The following equation was used to find out incorporation efficiency:

\[
\text{Incorporation efficiency (IE\%) = } \frac{(W_1 - W_2)}{W_1} \times 100 \tag{1}
\]

where “\( W_1 \)” and “\( W_2 \)” correspondingly represents weight of the total and nonentrapped drug in the SLN dispersion. Further, the following equation was used to obtain the total drug content in the SLNs:

\[
\text{Drug content(\%) = } \frac{C_1}{C_2} \times 100 \tag{2}
\]

Here, \( C_1 \) and \( C_2 \) correspondingly represent the practical and theoretical drug concentrations.

Measurement of Gelatin Temperature. Gelation temperature was measured by taking 8 g of TPT-SLNs-TRHS in a transparent glass vial. A small magnetic bar was placed inside the glass vial, which was further positioned on a water bath maintained at low temperature. A digital thermometer (IKA ETS-D5, China) was inserted in the glass vial to check the temperature of TPT-SLNs-TRHS. The water bath was at constant stirring of 50-80 rpm, and its temperature was steadily increased from 25°C to 47°C. The temperature at which the magnetic bar stopped rotation was noted as gelation temperature [34].

Gelation Time and Gel Strength. The change of the physical state of the TPT-SLNs-TRHS system from liquid form to gel was noted, and the time taken for this change was referred to as gelation time. Gel strength was the strength or viscosity of the TPT-SLNs-TRHS determined at 36.5°C. Brookfield cone and plate rheometer (DV3T, MA, USA) was used to examine the gelation time and gel strength of the TPT-SLNs-TRHS. Brookfield circulating temperature bath (TC150 MX, Middleboro, MA, USA) was used to control the temperature of the system [35].

Measurement of Bioadhesive Force. Male Sprague-Dawley rats aged 6-8 weeks and weighing 260 ± 20 g were sacrificed, and their rectums were used for measurement of bioadhesive force. Briefly, a physical balance was used for this purpose. A small portion of the rectal tissue was placed on each of the 2 glass vials. One of them was hanged from the physical balance. The other glass vial was fixed on movable pan using adhesive tape. A drop of TPT-SLNs-TRHS was placed on the rectal tissue in the fixed glass vial. Then, the movable pan was raised till both the vials got attached. Starting from minimum, various weights were added on the other pan of the balance until both vials separated. The smallest weight that detached the vials is called bioadhesive force represented here in dyne/cm² [34].

Transmission Electron Microscopy (TEM). Surface morphology of TPT-loaded SLNs and TPT-SLNs-TRHS were examined using TEM (Hitachi, Japan) that operates at 100 kV. A sample of the test formulation was diluted suitably and adsorbed on carbon-coated copper grid. The surface adsorbed test formulation was negatively stained with a drop of 1% phosphotungstic acid followed by drying at room temperature [36, 37].

In Vitro Cytotoxicity Studies. In vitro cytotoxicity study of TPT solution, conventional hydrogel, blank SLNs, and TPT-SLNs-TRHS was carried out using MTT colorimetric assay. The assay was carried out in a 96-well plate by seeding previously isolated cells (at concentration of 5 × 10⁴ cells/mL) and incubated for 24 h at 37°C and 5% CO₂ atmosphere. Then, cells were treated with a concentration range of test formulations followed by incubation at 37°C for 24 h. Afterwards, 20 μL of MTT solution was added to each plate followed by incubation for 4 h at 37°C. Then, 100 μL of DMSO (dimethyl sulfoxide) were added to each plate to dissolve obtained formazan crystal. Optical density (OD) was measured at 381 nm using a microplate reader [39].

The percentage cell viability was determined via the following equation:

\[
\%\text{Viability} = \frac{AT - AB}{AC - AB} \times 100 \tag{3}
\]

where AT is the OD of the treated sample, AC is the OD of the control, and AB is the OD of the blank samples.

Percentage of viable cell was subtracted from 100 in order to obtain percent cytotoxicity.
2.6.3. Pharmacokinetic Study

(1) Administration and Blood Collection. Pharmacokinetic studies were performed as per the previously used methods with some modifications [40, 41]. Three groups of rats with six rats in each group were categorized for animal study. After anaesthetising rats with trifluane, they were tied with thread on a surgical board in supine position. Blood samples were withdrawn from the femoral artery by inserting a polyethylene tube. One group of rats was intravenously (IV) administered with TPT solution in the left femoral vein while the other two groups were rectally administered with TPT-SLNs-TRHS system and conventional hydrogel, respectively at a dose of 10 mg/kg. Rectal administration was done with snore needle fixed on glass syringe, 4 cm above the rat anus. IV administered TPT solution acts as a control for the determination of absolute bioavailability of TPT. Periodic sampling (300 μL) was obtained from the femoral artery followed by centrifugation for 10 minutes at 9000 rpm. Plasma was separated and stored at -80°C followed by drug quantification through HPLC [42].

(2) Blood Treatment. For the quantification of TPT, 145 μL plasma was diluted with 145 μL of acetonitrile [43]. Additionally, 10 μL of acetonitrile solution containing 100 μg/mL irinotecan was added as an internal standard. Centrifugation of the mixture was performed in order to isolate the proteins. Finally, drug content in the supernatant was analysed via HPLC.

(3) Determination of Pharmacokinetic Parameters. Noncompartamental analysis was performed using WinNonlin software, (Apex, NC, USA) to check various pharmacokinetic parameters in individual rats [44]. These include maximum concentration (Cmax), maximum time to reach Cmax (Tmax), area under the curve (AUC) 0-infinity, and elimination constant (Kd). All the results were reported as mean ± standard deviation.

2.7. In Vivo Antitumour Efficacy. In vivo antitumour activity was determined by a xenograft model. Tumour was introduced by subcutaneously injecting 1 × 106 (100 μL) cells from a cancerous cell line SCCA into the right flanks (thighs) of all mice. When the tumour volume increased to 100-150 mm3, its treatment was started followed by subsequent doses at a specific time period. All 24 mice were categorized into 4 groups: the three experimental and one control groups. One experimental group was treated with intravenous solution of TPT at a dose of 5 mg/kg while the other two experimental groups were rectally administered with TPT-SLNs-TRHS and conventional hydrogel, respectively. The control group was left untreated. In each mouse, tumour length and width were measured with Vernier calipers and was calculated as follows: V = (length × width2)/2. Toxicity of each formulation was determined by investigating any changes in the body weight of their respective mouse group. The antitumour effect of the rectally administered TPT-SLNs-TRHS was analysed against rectally administered conventional hydrogel and IV administered TPT solution in the tumour-induced mice by observing tumour volume and body weight change. All mice were sacrificed after the completion of experiment [45, 46].

2.8. Morphological Characterization. Rats were rectally administered with TPT-SLNs-TRHS and conventional hydrogel. After 24 h of dose administration, the rectum was removed and washed with normal saline followed by fixation in 10% formaldehyde. Samples were embedded in petroleum wax and sliced in thin sections (3-4 μm). Morphological studies were conducted after staining with haematoxylin and eosin and observing results in Nikon microscope (Tokyo, Japan). Results of the untreated control group were compared with the experimental groups for changes in rectal tissues and epithelium. Some of the prominent changes seen in the experimental groups were deteriorating abrasions, epithelial shedding, atrophic changes in the mucosal membrane, and accumulation of inflammatory cells. A detailed analysis of the rectal tissue was done by calculating epithelial thickness (μm) and mean mucosal changes. Analysis was performed using automated image analyser (iSolution FL Quebec, Canada) [47, 48].

2.9. Statistical Analysis. t-test was applied for comparison and a P value less than 0.05 was considered statistically significant with 95% confidence interval. Multiple comparison tests for different dose groups were conducted. Variance homogeneity was examined using the Levene test. If the Levene test indicated no significant deviations from variance homogeneity, the data were analysed by one-way ANOVA test and the least significant difference (LSD) multicomparison test. In case of significant deviations from the variance, homogeneity was observed at Levene test, a nonparametric comparison test and the Kruskal–Wallis H test were conducted. Statistical analyses were conducted using SPSS for Windows (Release 21.0, SPSS Inc., USA).

2.10. Stability. Stability testing of the TPT-SLNs-TRHS was conducted for 6 months as reported earlier by [49]. The test formulation was stored at 25°C and 40°C, and samples were analysed for particle size and drug content at 0-, 2-, 4-, and 6-month intervals. Moreover, physical appearance of the test formulations was observed to find any precipitation.

3. Results and Discussion

3.1. Fabrication of TPT-SLNs-TRHS. The TPT-SLNs-TRHS were prepared by disseminating the TPT-loaded SLNs in thermoresponsive hydrogel. This TPT-SLNs-TRHS provide twofold control release of the drug owing to its incorporation in SLNs and the thermoresponsive hydrogel system. The SLNs were composed of (TPT/lipid/surfactant/water (1:0.5:0.5:10, w/v)), which showed mean particle size in nanorange (about 174 nm) with excellent incorporation efficiency (90%). Tricaprin was used as the lipid for the preparation of TPT-loaded SLNs. Tween 80 and Span 20 were, respectively, used as a surfactant and cosurfactant. Their proportion was adjusted as 4 to 1. The thermoresponsive hydrogel was composed of poloxamer solution at their weight ratio of (P 407/P 188/H2O (15:17:58%)). The TPT-SLNs-
TRHS was developed by incorporating TPT-loaded SLNs into the thermoresponsive hydrogel. The composition of the final formulation was 10 g of SLN incorporated into 32 g of poloxamer solution, which already contained 58 g double purified water. The TPT-SLNs-TRHS has gelation temperature of 31.9°C. Below this temperature, it remained a free flowing liquid whereas above this temperature, it is converted into gel (Figure 1). The SLNs and thermoresponsive hydrogel in the TPT-SLNs-TRHS was reported to overcome the erupted and quick release of the TPT, demonstrating a potential reduction in the associated toxicities. Moreover, it minimized the drug toxicity by preventing the direct contact of the TPT with rectal tissue.

3.2. Physicochemical Properties

3.2.1. Gelation Temperature. It is a temperature at which a thermoresponsive system changed its liquid state into gel. One of the requirements of thermoresponsive systems is that its gelation temperature should be in the range of 30–36°C [25, 48]. However, the gelation temperature value if above body temperature may lead to a leaking problem, whereas its value below ambient may result in the formation of hard gels at room temperature, which are not required in this case. Therefore, the poloxamer mixture was chosen because of their thermoresponsive gel formation characteristics in order to develop thermoresponsive namicelle [50]. Additionally, poloxamers have remarkable water solubilisation effect, abridged toxicity, suitable drug release profiles, rationally low levels of skin irritation, and high solubilizing ability [51, 52]. In a preliminary study, gelation temperature of TPT-SLNs-TRHS, which is the temperature at which the liquid change to gel, was determined as 31.9 ± 0.7°C. As can be seen in Figure 2, the TPT-SLNs-TRHS was free flowing at 25°C, but it was converted into gel right after its rectal administration. This thermoresponsive behaviour of the system was credited to the poloxamer solution, as it remains liquid at ambient condition; however, quickly transformed into gel, upon the exposure to physiological temperature. The means size of TPT incorporated SLN was around 174 nm via the DLS analysis which was further confirmed by TEM image as shown in Figures 3(a) and 3(b), respectively. TEM image demonstrated nanosized particles with uniform distribution and round shape [52, 53].

3.2.2. Dissolution Study. Figure 4(a) represents the dissolution summary of the TPT-SLNs-TRHS and conventional hydrogel. Both the test formulations were clear, owing to the solubilising effect of the poloxamer solution [19]. The TPT-SLNs-TRHS gave a meaningfully retarded dissolution rate of the TPT in association with the conventional hydrogel. An initial burst release was observed in conventional hydrogel as compared to the TPT-SLNs-TRHS. Conventional hydrogel dissolves 50% of the TPT in first 5 min followed by 82% dissolution in 60 minutes; however, the TPT-SLNs-TRHS slowly dissolve TPT, as 12% of it was dissolved in 5 min, trailed by 45% in 60 minutes. Thus, the drug dissolution was remarkably reduced by the TPT-SLNs-TRHS as compared to the conventional hydrogel, resulting in reduced burst effect. This reduced drug dissolution effect of the TPT-SLNs-TRHS could be attributed to its capability of double control on the incorporated drug in the form of TPT-loaded SLNs and thermoresponsive hydrogel.

3.3. In Vitro Cytotoxicity. Cytotoxicity profiles of TPT solution, conventional hydrogel, TPT-SLNs-TRHS, and blank SLNs were evaluated to know their efficacy against cancer cells (SSC-7) as represented in Figure 4(b). The cells were incubated at 0.5, 1.0, 2.5, 5.0, 12.5, 25.0, and 50.0 μg/mL drug concentrations. Blank SLNs did not display any considerable cytotoxicity for the complete range of concentrations. The cell viability persisted at more than 95% in all the cell lines even after 24 h of exposure to the formulations, indicating its biocompatible nature and tolerance [53, 54]. TPT solution demonstrated low cytotoxicity against the cancer cells as viability was reduced up to 62%; however, it was not up to the mark. This could be attributed to the cytotoxic effect of the TPT. However, since the TPT cleared quickly from the bloodstream, as demonstrated in pharmacokinetic studies, thus, its cytotoxic effect was not persistent [14]. The conventional hydrogel demonstrated a significantly enhanced cytotoxicity and considerably reduced cell viability as compared to the blank SLNs and TPT solution. It could be because of their better control of the cytotoxic drug against cancer cells. The conventional hydrogel when incorporated with anticancer agents demonstrated better release properties as compared to drug solution. TPT-SLNs-TRHS showed significantly enhanced cytotoxicity as compared to blank SLNs and TPT. Further, it demonstrated significantly
reduced cell viability, as almost all the cancer cells died after treatment with TPT-SLNs-TRHS. This could be because of the highly cytotoxic nature of the TPT which was potentiated by the sustained release behaviour and long-time blood circulation of the NLCs. Furthermore, the drug release was dually controlled by SLNs and TRHS which leads to enhanced cytotoxicity.

3.3.1. Rectal Pharmacokinetic Study. To obtain the pharmacokinetic profiles of the TPT-SLNs-TRHS and conventional hydrogel, they were rectally administered at a dose of 10 mg/kg, whereas TPT solution was given intravenously, at equivalent dose. The findings are represented in Figure 5 and Table 1. As expected, the TPT solution eliminated quickly from the blood flow (3-6 h) right after their IV

---

**Figure 2:** Measurement of gelation temperature at 25°C and 36.5°C. (a) The liquid behaviour at ambient temperature. (b) The gelation behaviour at physiological temperature.

**Figure 3:** Particle characterization. (a) Mean particle size via Zetasizer. (b) Particle morphology via TEM 5001x.
administration exhibiting a linear pharmacokinetics (Figure 5(a)) [45, 46]. The conventional hydrogel showed an early release of drug just after the rectal administration followed by a maximum plasma concentration (112.6 ng/mL) at 1.4 h trailed by gradual decrease until 1.51 ng/mL at 24 h. However, the TPT-SLNs-TRHS achieved a maximum plasma level of about 77.69 ng/mL at 2 h and maintained a level of 1.29 μg/mL at 24 h, even if the initial drug release was slower than the conventional hydrogel (Figure 5(b)). There was no significant difference between the maximum plasma concentration of conventional hydrogel and TPT-SLNs-TRHS; however, the maximum time required to reach
the climax for conventional hydrogel was significantly lower than that of TPT-SLNs-TRHS which showed that burst release may occur in case of the conventional hydrogel, leading to the drug toxicity [55]. The AUC of the intravenously administered TPT solution was 1375.34 ± 139.74 ng h/mL, thus significantly higher than the AUC of TPT-SLNs-TRHS 456.23 ± 59.62 ng h/mL and hydrogel 193.69 ± 17.31 ng h/mL. However, the AUC of TPT-SLNs-TRHS was higher but not significantly different than that of conventional hydrogel. The relatively high AUC, half-life, and lower elimination rate in the TPT-SLNs-TRHS shows that the drug was released in a more retarded way as compared to the conventional hydrogel, leading to delayed drug release. Our results suggested that unlike TPT-SLNs-TRHS, a burst release may occur in TPT solution and conventional hydrogel, leading to the direct interaction of drug to body tissue which may cause tissue toxicity and side effects.

3.3.2. Morphology of the Rectal Tissue. Rectal tissue was examined for changes in its morphology within two

| Parameters       | TPT solution (IV) | Conventional hydrogel | TPT-SLNs-TRHS | TPT solution (IV) |
|------------------|-------------------|-----------------------|---------------|-------------------|
| AUC (ng h/mL)    | 1375.34 ± 139.74**| 163.69 ± 17.31        | 456.23 ± 59.62* | 1375.34 ± 139.74**|
| T<sub>max</sub>(h) | —                 | 1.43 ± 0.30           | 2.01 ± 0.30*   | —                 |
| C<sub>max</sub> (ng/mL) | 940.67 ± 80.89**  | 77.69 ± 17.53         | 112.60 ± 25.43* | 940.67 ± 80.89**  |

Each value represents the mean ± S.D (n = 6). *P < 0.05 compared to conventional hydrogel. **P < 0.05 compared to conventional hydrogel and TPT-SLNs-TRHS.

![Figure 6](image_url)

**Figure 6:** Morphology of the rectal mucosa of rats after administration of the control (a), TPT-SLNs-TRHS (b), and conventional hydrogel (c). EP: epithelium; LU: lumen; MM: muscularis mucosa; MU: mucosal layer. Scale bars = 100 μm.

| Morphology          | Control       | Conventional hydrogel | TPT-SLNs-TRHS |
|---------------------|---------------|-----------------------|--------------|
| Mucosa thickness (μm) | 301.42 ± 29.23 | 212.97 ± 16.42*       | 298.33 ± 27.17 |
| Epithelial thickness (μm) | 41.52 ± 5.92  | 22.61 ± 3.96*         | 39.45 ± 4.02  |
| Collagen percentage (%/mm²) | 126.16 ± 29.93 | 175.32 ± 54.21*       | 127.54 ± 31.58 |
| Mononuclear cell numbers (cells/mm²) | 43.53 ± 6.73  | 41.25 ± 5.94          | 42.73 ± 5.34  |

Each histological value represents the mean ± S.D (n = 9). *P < 0.05 compared to the control and TPT-SLNs-TRHS.
experimental groups treated with TPT-SLNs-TRHS and conventional hydrogel and untreated control groups (Figure 6). Generally, TPT is a known cytotoxic drug and causes cell lyses, irritation, and damage to the epithelium tissues when exposed directly. Conventional hydrogel directly released drug to rectal tissues leading to irritation and damage [55].

Rectal application of TPT-SLNs-TRHS caused no considerable change leading to irritation or damage to rectal tissue when compared with the untreated control group (Figures 6(a) and 6(b)). Moreover, no change in the thickness of the rectal epithelium or any change in the amount of mononuclear cells in lamina propria was demonstrated in
### Table 3: Stability test of the TPT-SLNs-TRHS at various storage conditions.

| Period (months) | Particle size (nm) | Drug content (%) | Physical appearance |
|-----------------|--------------------|------------------|---------------------|
|                 | 0                  | 2 4 6            | 2 4 6               |                     |
| 25°C            | 174.4 ± 12.3       | 176.1 ± 11.2     | 178.6 ± 10.4        | 181.5 ± 9.8 100     | 99.1 ± 0.2 98.2 ± 0.3 | 97.8 ± 0.4 Clear Clear Clear Clear |
| 40°C            | 174.4 ± 12.3       | 177.5 ± 12.3     | 180.7 ± 11.9        | 188.6 ± 9.7 100     | 97.0 ± 0.5 92.3 ± 0.4 | 90.2 ± 0.6 Clear Clear Cloudy Precipitation |

Each value represents the mean ± SD (n = 3).
the TPT-SLNs-TRHS-treated group (Table 2). It was because of the thermoresponsive nature of the TPT-SLNs-TRHS system leading to the controlled release of the drug and minimizing signs of irritation, damage, or toxicity. However, conventional hydrogel caused severe damage to the rectal tissue as evident in Figure 6(c).

3.3.3. In Vivo Antitumour Ability. Antitumour effectiveness of the test formulations (TPT-SLNs-TRHS, TPT solution, and conventional hydrogel) was determined, and their ability to suppress the tumour was compared with one another. The tumour expression was conducted in xenograft nude mice and assessed on the bases of tumour growth and volume. Further, the body weights of the mice were also analysed throughout the experimentation [56, 57]. As can be seen, a significant decrease in tumour cell volumes were observed in order of the TPT-SLNs-TRHS followed by conventional hydrogel and TPT solution, as compared with the untreated control group, after rectal administration of TPT-SLNs-TRHS and conventional hydrogel, and IV administration of the TPT solution. Moreover, no body weight loss or gain was perceived in TPT-SLNs-TRHS-treated mice in association to the conventional hydrogel and TPT solution-treated groups. Consequently, the antitumour effectiveness of TPT can be enhanced by using TPT-SLNs-TRHS as a drug delivery carrier, most particularly than those of conventional hydrogel and TPT solution as demonstrated in this experiment. Figure 7 depicts the antitumour activities of the rectally administered TPT-SLNs-TRHS and conventional hydrogel and their comparison with IV administered TPT solution. The tumour growth was consistent in all the test groups after 5 days, until they received 1st dose of the respective drug formulations (Figure 7(a)). The meaningfully increased tumour volume was observed in the control group because no treatment was provided to these mice. Unlikely, a significantly decreased tumour volume was observed in TPT solution \( (P < 0.05, 8-30 \text{ days}) \), TPT-SLNs-TRHS, and conventional hydrogel-treated groups as compared to the control group. Moreover, the outcomes of this study indicated a significantly increased tumour volume \( (P < 0.05, 8-30 \text{ days}) \) of the TPT solution group as compared to the TPT-SLNs-TRHS and conventional hydrogel, which can be attributed to its quick elimination from the blood stream as demonstrated in pharmacokinetics study [45, 58]. On the other hand, mice treated with TPT-SLNs-TRHS showed a significantly decreased tumour volume as compared to the conventional hydrogel.

Toxicity profiles of the test preparations were evaluated based on variation in their body weight over the extend period of study time. The TPT solution was IV administered, while the TPT-SLNs-TRHS and conventional hydrogel were given rectally. The results are demonstrated in Figure 7(b). As expected, the body weight of the control group mice was meaningfully increased as compared to the TPT-SLNs-TRHS and conventional hydrogel \( (P < 0.01, 15-18 \text{ days}) \). Also, the TPT solution-treated group mice exhibited a substantial body weight loss when compared with the TPT-SLNs-TRHS and conventional hydrogel \( (P < 0.05, 11-22 \text{ days}) \) and the untreated group \( (P < 0.05, 8-22 \text{ days}) \). Furthermore, the mice treated with TPT-SLNs-TRHS and conventional hydrogel retained their body weight until the completion of study (day 22). After which, the conventional hydrogel-treated mouse weight becomes significantly different than the TPT-SLNs-TRHS \( (P < 0.05, 22 \text{ day}) \). This could be because of the double control over the release of TPT when incorporated in TPT-SLNs-TRHS, which may prolong the release over an extended period of time leading to better antitumour effect and no toxicity. Beside this, the tumour mass was also observed and represented in Figure 7(c). The tumour mass was significantly large in the untreated control, TPT solution, and conventional hydrogel, respectively, as compared to the TPT-SLNs-TRHS. Our results suggested that the TPT-SLNs-TRHS did not induce toxicity of the loaded antitumour drug. However, the substantial body weight loss in the TPT solution and conventional hydrogel-treated mouse groups indicated severe toxicity of the loaded drug [59]. The weight gained by the untreated mouse group could be attributed to an increase in the tumour volume.

3.3.4. Stability. Stability studies of the TPT-SLNs-TRHS were conducted for 6 months at ambient and physiological temperatures. The parameters used for stability analysis included physical appearance, drug content, and mean particle size. No substantial alteration was observed in the physical appearance, drug content, and mean particle size of the drug during the study duration period. Moreover, the TPT content decreased by less than 10%, even at elevated temperature of 40°C (Table 3), suggesting that TPT-SLNs-TRHS was stable for at least 6 months.

4. Conclusions

It is concluded that TPT was successfully incorporated into the SLN system which was further homogeneously dispersed in thermoresponsive hydrogel to develop TPT-SLNs-TRHS. This formulation was able to respond to temperature change and was suitable for rectal administration. Developed TPT-SLNs-TRHS was able to prevent initial burst release which could cause toxicity to rectum tissue and localized muscle tissues. Pharmacokinetic studies reveal that the TPT-SLNs-TRHS was suitable for sustained release effect in vivo. Stability studies exhibited that no considerable alteration in particle size and incorporation efficiency was seen over a period of six months. Further, the prepared formulation demonstrated an enhanced antitumour potential as compared to the pure drug solution. These results conclude that TPT-SLNs-TRHS is a successful candidate possessing enhanced antitumour efficacy and reduced toxicity effects.

Data Availability

All the data related to this study are mentioned in the manuscript. Any further data if required may be obtained on request from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.
Authors’ Contributions

Ruo Xing performed data curation and investigation and acquired funding. Omer Mustapha wrote the 2nd draft and did the review and editing. Tariq Ali did the methodology and wrote first draft. Mujeeb ur Rehman performed the formal analysis and acquired software. Syed Saoud Zaidi performed data curation and acquired software. Abdul Baseer did the conceptualization and data curation. Sibgah Batool performed the formal analysis and investigation and reviewed the first draft. Muhammad Mukhtiar did the interpretation and performed the formal analysis. Shumaila Shafi-que drafted the manuscript and performed the formal analysis. Zakir Ali did the methodology and investigation. Fatima Zahid did the validation and wrote the second draft. Alam Zeb did the administration and acquired resources. Fawad Ali Shah critically revised the manuscript and supervised the study. Abid Mehmooid Youas acquired resources and did the visualization. Fakhar ud Din did the conceptualization, acquiring of funding, administration, and final approval.

Acknowledgments

The authors are very much thankful to the Hanyang University South Korea and Riphah International University Islamabad Pakistan for providing technical support. The authors are also grateful to the NIH, Pakistan for providing access to their research facilities. This project was financially supported by the Higher Education Commission of Pakistan via grant (No. 21-836/SRGP/R&D/HEC/2016). Moreover, partial support was provided by Quaid-i-Azam University Islamabad through the University research fund (URF).

References

[1] L. Souza, E. Silva, A. Martins et al., “Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 79, no. 1, pp. 189–196, 2011.
[2] J. Fassberg and V. J. Stella, “A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues,” Journal of Pharmaceutical Sciences, vol. 81, no. 7, pp. 676–684, 1992.
[3] M. Mir, S. Ishiaq, S. Rabia et al., “Nanotechnology: from in vivo imaging system to controlled drug delivery,” Nanoscale Research Letters, vol. 12, no. 1, pp. 500–516, 2017.
[4] J. H. Venâncio, L. M. Andrade, N. L. S. Esteves et al., “Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers,” Journal of Pharmacy and Pharmacology, vol. 69, no. 10, pp. 1318–1326, 2017.
[5] B. Shen, K. Zhao, S. Ma, D. Yuan, and Y. Bai, “Topotecan-loaded Mesoporous silica nanoparticles for reversing multidrug resistance by synergetic chemoradiotherapy,” Chemistry–An Asian Journal, vol. 10, no. 2, pp. 344–348, 2015.
[6] Z.-j. Chen, Z. Zhang, B.-b. Xie, and H.-y. Zhang, “Development and evaluation of topotecan loaded solid lipid nanoparticles: a study in cervical cancer cell lines,” Journal of Photochemistry and Photobiology B: Biology, vol. 165, pp. 182–188, 2016.
[7] A. M. Vali, T. Toliyat, B. Shafaghi, and S. Dadashzadeh, “Preparation, optimization, and characterization of topotecan loaded PE Gylated liposomes using factorial design,” Drug Development and Industrial Pharmacy, vol. 34, no. 1, pp. 10–23, 2008.
[8] F. r. Din, J. Y. Choi, D. W. Kim et al., “Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration,” Drug Delivery, vol. 24, no. 1, pp. 502–510, 2017.
[9] K. Rajpoot and S. K. Jain, “Oral delivery of pH-responsive alginate microbeads incorporating folic acid-grafted solid lipid nanoparticles exhibits enhanced targeting effect against colorectal cancer: a dual-targeted approach,” International Journal of Biological Macromolecules, vol. 151, pp. 830–844, 2020.
[10] K. Rajpoot and S. K. Jain, “99mTc-labelled and pH-awakened microbeads entrapping surface-modified lipid nanoparticles for the augmented effect of oxaliplatin in the therapy of colorectal cancer,” Journal of Microencapsulation, vol. 37, no. 8, pp. 609–623, 2020.
[11] H. Li, X. Zhao, Y. Ma, G. Zhai, L. Li, and H. Lou, “Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles,” Journal of Controlled Release, vol. 133, no. 3, pp. 238–244, 2009.
[12] L. Rana, N. Khan, M. M. Ansari et al., “Solid lipid nanoparticles-mediated enhanced antidepressant activity of duloxetine in lipopolysaccharide-induced depressive model,” Colloids and Surfaces B: Biointerfaces, vol. 194, p. 111209, 2020.
[13] K. Rajpoot and S. K. Jain, “Irinotecan hydrochloride trihydrate loaded folic acid-tailored solid lipid nanoparticles for targeting colorectal cancer: development, characterization, and in vitro cytotoxicity study using HT-29 cells,” Journal of Microencapsulation, vol. 36, no. 7, pp. 659–676, 2019.
[14] F. r. Din, Y. Choi, D. W. Kim et al., “Irinotecan-loaded double-reversible thermogel with improved antitumor efficacy without initial burst effect and toxicity for intramuscular administration,” Acta Biomaterialia, vol. 54, pp. 239–248, 2017.
[15] F. u. Din, W. Aman, I. Ullah et al., “Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors,” International Journal of Nanomedicine, vol. Volume 12, pp. 7291–7309, 2017.
[16] H. Jamshaid, F., Din, and G. M. Khan, “Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight,” Journal of Nanobiotechnology, vol. 19, no. 1, pp. 106–151, 2021.
[17] R. H. Müller, K. Mäder, and S. Gohl, “Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 161–177, 2000.
[18] H. Hajipour, H. Hamishehkar, M. Rahmati-yamchi, D. Shamehbandi, S. Nazari Soltan Ahmad, and A. Hasani, “Enhanced anti-cancer capability of ellagic acid using solid lipid nanoparticles (SLNs),” International Journal of Cancer Management, vol. 11, no. 1, 2018.
[19] Fakhar-ud-Din and G. M. Khan, “Development and characterisation of levosulpiride-loaded suppositories with improved bioavailability in vivo,” Pharmaceutical Development and Technology, vol. 24, no. 1, pp. 63–69, 2019.
G. Yu, M. I. Asad, M. Qindeel et al., “Polymeric nanogels as versatile nanoplatforms for biomedical applications,” Journal of Nanomaterials, vol. 2019, Article ID 1526186, 16 pages, 2019.

D. de Araújo, A. C. Mendonça dos Santos, A. C. Santos Akkari et al., “Poloxamer-based binary hydrogels for delivering tramadol hydrochloride: sol-gel transition studies, dissolution-release kinetics, in vitro toxicity, and pharmacological evaluation,” International Journal of Nanomedicine, vol. 10, p. 2391, 2015.

F. Din, S. G. Jin, and H. G. Choi, “Particle and gel characterization of irinotecan-loaded double-reverse thermosensitive hydrogel,” Polymers, vol. 13, no. 4, p. 551, 2021.

U. Posadowska, M. Parizek, E. Filova et al., “Injectable nanoparticle-loaded hydrogel system for local delivery of sodium alendronate,” International Journal of Pharmaceutics, vol. 485, no. 1-2, pp. 31–40, 2015.

J. Raymond, A. Metcalfe, I. Salazkin, and A. Schwarz, “Temporary vascular occlusion with poloxamer 407,” Biomaterials, vol. 25, no. 18, pp. 3983–3989, 2004.

C. S. Yong, Y.-K. Oh, S. H. Jung et al., “Preparation of ibuprofen-loaded liquid suppository using eutectic mixture system with menthol,” European Journal of Pharmaceutical Sciences, vol. 23, no. 4-5, pp. 347–353, 2004.

S. K. Ramadass, S. Perumal, S. L. Jabaris, and B. Madhan, “Preparation and evaluation of mesalamine collagen _in situ_ rectal gel: a novel therapeutic approach for treating ulcerative colitis,” European Journal of Pharmaceutical Sciences, vol. 48, no. 1-2, pp. 104–110, 2013.

G. Yu, Z. Ali, A. Sajjad Khan et al., “Preparation, pharmacokinetics, and antitumor potential of miltefosine-loaded nanostructured lipid carriers,” International Journal of Nanomedicine, vol. 16, pp. 3255–3273, 2021.

S. A. Khan, F. Ud Din, Z. Ali et al., “Development, in vitro and in vivo evaluation of miltefosine loaded nanostructured lipid carriers for the treatment of _cutaneous leishmaniasis_,” International Journal of Nanomedicine, vol. 593, p. 120109, 2021.

N. Khan, F. A. Shah, I. Rana et al., “Nanostructured lipid carriers-mediated brain delivery of carbamazepine for improved _in vivo_ anticonvulsant and anxiolytic activity,” International Journal of Pharmaceutics, vol. 577, p. 119033, 2020.

F. Din, A. Zeb, K. U. Shah, and Zia-ur-Rehman, “Development, _in-vitro_ and _in-vivo_ evaluation of ezetimibe-loaded solid lipid nanoparticles and their comparison with marketed product,” Journal of Drug Delivery Science and Technology, vol. 51, pp. 583–590, 2019.

N. Khaleeq, F.-U. Din, A. S. Khan, S. Rabia, J. Dar, and G. M. Khan, “Development of levosulpiride-loaded solid lipid nanoparticles and their in vitro and in vivo comparison with commercial product,” Journal of Microencapsulation, vol. 37, no. 2, pp. 160–169, 2020.

D. L. Warner and T. G. Burke, “Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylic forms of camptothecin anticancer drugs,” Journal of Chromatography B: Biomedical Sciences and Applications, vol. 691, no. 1, pp. 161–171, 1997.

Y. G. Seo, D.-W. Kim, W. H. Yeo et al., “Docetaxel-loaded thermosensitive and bioadhesive nanomicelles as a rectal drug delivery system for enhanced chemotherapeutic effect,” Pharmaceutical Research, vol. 30, no. 7, pp. 1860–1870, 2013.
mice,” *Biochemical and Biophysical Research Communications*, vol. 410, no. 3, pp. 434–439, 2011.

[48] H.-G. Choi, J.-H. Jung, J.-M. Ryu, S.-J. Yoon, Y.-K. Oh, and C.-K. Kim, “Development of in situ-gelling and mucoadhesive acetaminophen liquid suppository,” *International Journal of Pharmaceutics*, vol. 165, no. 1, pp. 33–44, 1998.

[49] S. Batool, F. Zahid, F. Ud-Din et al., “Macrophage targeting with the novel carbopol-based miltefosine-loaded transferosomal gel for the treatment of cutaneous leishmaniasis: in vitro and in vivo analyses,” *Drug Development and Industrial Pharmacy*, vol. 47, no. 3, pp. 440–453, 2021.

[50] L. Mayol, M. Biondi, F. Quaglia et al., “Injectable thermally responsive mucoadhesive gel for sustained protein delivery,” *Biomacromolecules*, vol. 12, no. 1, pp. 28–33, 2011.

[51] D. W. Kim, M. S. Kwon, A. M. Yousaf et al., “Comparison of a solid SMEDDS and solid dispersion for enhanced stability and bioavailability of clopidogrel napadisilate,” *Carbohydrate Polymers*, vol. 114, pp. 365–374, 2014.

[52] M. W. Salim, K. Shabbir, F. ud-Din, A. M. Yousaf, H. G. Choi, and G. M. Khan, “Preparation, in-vitro and in-vivo evaluation of rifampicin and vancomycin co-loaded transferosomal gel for the treatment of cutaneous leishmaniasis,” *Journal of Drug Delivery Science and Technology*, vol. 60, p. 101996, 2020.

[53] S. Petersen, F. Steiniger, D. Fischer, A. Fahr, and H. Bunjes, “The physical state of lipid nanoparticles influences their effect on in vitro cell viability,” *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 79, no. 1, pp. 150–161, 2011.

[54] T. H. Tran, J. Y. Choi, T. Ramasamy et al., “Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells,” *Carbohydrate Polymers*, vol. 114, pp. 407–415, 2014.

[55] S. Pacelli, F. Acosta, A. R. Chakravarti et al., “Nanodiamond-based injectable hydrogel for sustained growth factor release: preparation, characterization and in vitro analysis,” *Acta Biomaterialia*, vol. 58, pp. 479–491, 2017.

[56] J. Y. Choi, T. Ramasamy, T. H. Tran et al., “Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth,” *Journal of Materials Chemistry B*, vol. 3, no. 3, pp. 408–416, 2015.

[57] S. Manchun, C. R. Dass, K. Cheewatanakornkool, and P. Srimoronsak, “Enhanced anti-tumor effect of pH-responsive dextrin nanogels delivering doxorubicin on colorectal cancer,” *Carbohydrate Polymers*, vol. 126, pp. 222–230, 2015.

[58] J.-Y. Kim, J.-K. Kim, J.-S. Park, Y. Byun, and C.-K. Kim, “The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator,” *Biomaterials*, vol. 30, no. 29, pp. 5751–5756, 2009.

[59] E. Cetinkaya, S. Abdullazade, C. Sokmensuer, and O. Abbasoglu, “Effect of irinotecan on liver regeneration: an experimental study in rats,” *Hepato-Gastroenterology*, vol. 61, no. 136, pp. 2291–2294, 2014.